First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan-Reference-Cited by-同舟云学术

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

Published:2022-09 Issue:9 Volume:3 Page:100397
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Goto Yasushi^ORCID,Tamura Atsuhisa,Matsumoto Hirotaka,Isobe Kazutoshi,Ozaki Tomohiro,Santorelli Melissa L.,Taniguchi Kazuko,Kamitani Tetsu,Irisawa Masato,Kanda Kingo,Abe Machiko,Burke Thomas,Nokihara Hiroshi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%;Reck;J Clin Oncol,2021

3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

4. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients;Sekine;Cancer Sci,2020

5. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions;Sedrak;CA Cancer J Clin,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

2. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

3. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study);Cancers;2024-05-08

4. Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab;Clinical Lung Cancer;2023-09

5. Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer;Cancer Medicine;2023-03-31